Lymphangiomas, also called lymphatic malformations, are noncancerous, fluid-filled cysts that occur in lymphatic vessels. These vessels contain a substance called lymph, and together they make up the lymphatic system. Lymph helps to properly regulate fluid in body tissue. Along with blood vessels, lymphatic vessels play an important role in the circulation of body fluid and the recruitment of immune cells.
Thus far, the etiology and molecular biological mechanisms of lymphatic abnormalities are not very clear. A better understanding of the pathogenesis of lymphangioma is required to develop more effective diagnosis and treatment strategies, improve the curative effects, reduce side effects, and achieve accurate treatments. Recently, rapid progress has been made toward elucidating the molecular pathology of lymphangioma and the development of treatments using computational approaches. Several signaling pathways have been revealed to be involved in the progression and development of lymphangioma, such as RAS/RAF/MEK/ERK/PI3K/AKT/mTOR signaling pathways, and specific inhibitors targeting these pathways have been investigated for clinical applications and clinical trials.
Our mission is to uncover the mechanisms of lymphangioma. We utilize microarray, deep sequencing platforms, advanced biostatistical and computational analyses methods to detect biological signals in highly dimensional and often noisy genomic data. We are also interested in how the machine learning-based integration of multi-omic datasets can aid in the discovery of new cancer subgroups and biomarkers.
In addition, CD ComputaBio has multiple resources including academic research and preclinical works in the identification of a suitable disease target and its corresponding hit. Contact us for more service details.
Reference